New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review

Curr Oncol. 2022 Apr 17;29(4):2835-2847. doi: 10.3390/curroncol29040231.

Abstract

This review of the meaningful data from 2021 on cervical, endometrial, and ovarian cancers aims to provide an update of the most clinically relevant studies presented at important oncologic congresses during the year (the American Society of Clinical Oncology (ASCO) Annual Meeting, the European Society for Medical Oncology (ESMO) Congress and the Society of Gynecologic Oncology (SGO) Annual Meeting). Despite the underlying existence of the COVID-19 pandemic, the last year has been notable in terms of research, with significant and promising advances in gynecological malignancies. Several major studies reporting the effects of innovative therapies for patients with cervical, endometrial, and ovarian cancers might change the medical practice in the future.

Keywords: 2021 update; cervical cancer; endometrial cancer; immunotherapy; novel targeted therapies; ovarian cancer.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Female
  • Gynecology*
  • Humans
  • Medical Oncology
  • Ovarian Neoplasms* / drug therapy
  • Pandemics